P2X7 receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness

Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, Wieckowski MR et al. (2005). Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell 16: 3260–3272.

Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P et al. (2010). Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. Faseb J 24: 3393–3404.

Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A et al. (2002). P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 99: 706–708.

Burnstock G . (2006). Purinergic signalling. Br J Pharmacol 147: S172–S181.

Cabrini G, Falzoni S, Forchap SL, Pellegatti P, Balboni A, Agostini P et al. (2005). A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J Immunol 175: 82–89.

Chantome A, Girault A, Potier M, Collin C, Vaudin P, Pages JC et al. (2009). KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp Cell Res 315: 3620–3630.

Deli T, Varga N, Adam A, Kenessey I, Raso E, Puskas LG et al. (2007). Functional genomics of calcium channels in human melanoma cells. Int J Cancer 121: 55–65.

Di Virgilio F, Chiozzi P, Falzoni S, Ferrari D, Sanz JM, Venketaraman V et al. (1998). Cytolytic P2X purinoceptors. Cell Death Differ 5: 191–199.

Di Virgilio F, Ferrari D, Adinolfi E . (2009). P2X(7): a growth-promoting receptor-implications for cancer. Purinergic Signal 5: 251–256.

Donnelly-Roberts DL, Jarvis MF . (2007). Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 151: 571–579.

Egeblad M, Werb Z . (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174.

Frosch BA, Berquin I, Emmert-Buck MR, Moin K, Sloane BF . (1999). Molecular regulation, membrane association and secretion of tumor cathepsin B. Apmis 107: 28–37.

Gillet L, Roger S, Besson P, Lecaille F, Gore J, Bougnoux P et al. (2009). Voltage-gated sodium channel activity promotes cysteine cathepsin-dependent invasiveness and colony growth of human cancer cells. J Biol Chem 284: 8680–8691.

Gupta GP, Massague J . (2006). Cancer metastasis: building a framework. Cell 127: 679–695.

Hibell AD, Kidd EJ, Chessell IP, Humphrey PP, Michel AD . (2000). Apparent species differences in the kinetic properties of P2X(7) receptors. Br J Pharmacol 130: 167–173.

Jedeszko C, Sloane BF . (2004). Cysteine cathepsins in human cancer. Biol Chem 385: 1017–1027.

Li X, Zhou L, Feng YH, Abdul-Karim FW, Gorodeski GI . (2006). The P2X7 receptor: a novel biomarker of uterine epithelial cancers. Cancer Epidemiol Biomarkers Prev 15: 1906–1913.

Lopez-Castejon G, Theaker J, Pelegrin P, Clifton AD, Braddock M, Surprenant A . (2010). P2X(7) receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially involved in joint diseases. J Immunol 185: 2611–2619.

Marques IJ, Weiss FU, Vlecken DH, Nitsche C, Bakkers J, Lagendijk AK et al. (2009). Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model. BMC Cancer 9: 128.

Mohamed MM, Sloane BF . (2006). Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6: 764–775.

North RA . (2002). Molecular physiology of P2X receptors. Physiol Rev 82: 1013–1067.

Pelegrin P, Surprenant A . (2006). Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. Embo J 25: 5071–5082.

Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F . (2008). Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 3: e2599.

Potier M, Joulin V, Roger S, Besson P, Jourdan ML, Leguennec JY et al. (2006). Identification of SK3 channel as a new mediator of breast cancer cell migration. Mol Cancer Ther 5: 2946–2953.

Potier M, Tran TA, Chantome A, Girault A, Joulin V, Bougnoux P et al. (2010). Altered SK3/KCa2.3-mediated migration in adenomatous polyposis coli (Apc) mutated mouse colon epithelial cells. Biochem Biophys Res Commun 397: 42–47.

Raffaghello L, Chiozzi P, Falzoni S, Di Virgilio F, Pistoia V . (2006). The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer Res 66: 907–914.

Rassendren F, Buell GN, Virginio C, Collo G, North RA, Surprenant A . (1997). The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 272: 5482–5486.

Rodriguez A, Webster P, Ortego J, Andrews NW . (1997). Lysosomes behave as Ca2+-regulated exocytic vesicles in fibroblasts and epithelial cells. J Cell Biol 137: 93–104.

Roger S, Gillet L, Baroja-Mazo A, Surprenant A, Pelegrin P . (2010a). C-terminal calmodulin-binding motif differentially controls human and rat P2X7 receptor current facilitation. J Biol Chem 285: 17514–17524.

Roger S, Mei ZZ, Baldwin JM, Dong L, Bradley H, Baldwin SA et al. (2010b). Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res 44: 347–355.

Roger S, Pelegrin P, Surprenant A . (2008). Facilitation of P2X7 receptor currents and membrane blebbing via constitutive and dynamic calmodulin binding. J Neurosci 28: 6393–6401.

Roger S, Potier M, Vandier C, Besson P, Le Guennec JY . (2006). Voltage-gated sodium channels: new targets in cancer therapy? Curr Pharm Des 12: 3681–3695.

Roger S, Rollin J, Barascu A, Besson P, Raynal PI, Iochmann S et al. (2007). Voltage-gated sodium channels potentiate the invasive capacities of human non-small-cell lung cancer cell lines. Int J Biochem Cell Biol 39: 774–786.

Roshy S, Sloane BF, Moin K . (2003). Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev 22: 271–286.

Shemon AN, Sluyter R, Fernando SL, Clarke AL, Dao-Ung LP, Skarratt KK et al. (2006). A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem 281: 2079–2086.

Slater M, Danieletto S, Barden JA . (2005). Expression of the apoptotic calcium channel P2X7 in the glandular epithelium. J Mol Histol 36: 159–165.

Slater M, Danieletto S, Gidley-Baird A, Teh LC, Barden JA . (2004a). Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology 44: 206–215.

Slater M, Danieletto S, Pooley M, Cheng Teh L, Gidley-Baird A, Barden JA . (2004b). Differentiation between cancerous and normal hyperplastic lobules in breast lesions. Breast Cancer Res Treat 83: 1–10.

Solini A, Cuccato S, Ferrari D, Santini E, Gulinelli S, Callegari MG et al. (2008). Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology 149: 389–396.

Surprenant A, Rassendren F, Kawashima E, North RA, Buell G . (1996). The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272: 735–738.

Wang Q, Wang L, Feng YH, Li X, Zeng R, Gorodeski GI . (2004a). P2X7 receptor-mediated apoptosis of human cervical epithelial cells. Am J Physiol Cell Physiol 287: C1349–C1358.

Wang X, Arcuino G, Takano T, Lin J, Peng WG, Wan P et al. (2004b). P2X7 receptor inhibition improves recovery after spinal cord injury. Nat Med 10: 821–827.

Zhang XJ, Zheng GG, Ma XT, Yang YH, Li G, Rao Q et al. (2004). Expression of P2X7 in human hematopoietic cell lines and leukemia patients. Leuk Res 28: 1313–1322.